| Bioactivity | Etofylline clofibrate has ypolipidemic and antithrombotic effect. Etofylline clofibrate has an agonistic interaction with intimal PGI2[1]. | ||||||||||||
| In Vivo | Etofylline clofibrate (p.o.; 12 mg/kg) has the moderate effect of a single dose (12% reduction in disaggregation time) and has a maximum reduction of 31 and 43% following 5 and 7 consecutive daily applications, respectively[1]. | ||||||||||||
| Name | Etofylline clofibrate | ||||||||||||
| CAS | 54504-70-0 | ||||||||||||
| Formula | C19H21ClN4O5 | ||||||||||||
| Molar Mass | 420.85 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Metz G, et al. Effect of etofylline clofibrate on experimental thrombus formation and prostacyclin activation. Arzneimittelforschung. 1986 Sep;36(9):1363-5. |
Etofylline clofibrate
CAS: 54504-70-0 F: C19H21ClN4O5 W: 420.85
Etofylline clofibrate has ypolipidemic and antithrombotic effect. Etofylline clofibrate has an agonistic interaction wit
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.